Abstract Background Remote monitoring in IBD may help identify patients at risk of higher healthcare use. The TrueColours-IBD (TC-IBD) system, initiated at the Oxford University Hospitals in 2018, enables patients to report baseline case mix variables, weekly symptoms (HBI for CD; SCCAI for UC), fortnightly health-related quality of life (HRQoL - derived from the EQ-5D), and three-monthly healthcare use (ICHOM). We identified factors associated with hospitalisation, emergency department (ED) admission, and related costs using the longitudinal TC-IBD data. Methods Adults with IBD enrolled in TC-IBD (June 2018–Feb 2025) and ≥6 months of follow-up were included. Data were aggregated into 3-month panels using the most severe values within each period, and 3-month lagged variables to ensure temporal ordering. Random-effects logistic regression examined associations between HBI, SCCAI and EQ-5D scores, and subsequent hospitalisation or ED visits, adjusting for demographic and clinical covariates. Annual costs were calculated using reported hospital use and unit costs, and population-level costs estimated by applying average per-patient event rates to the UK IBD population. Analyses were performed in Stata 19. Results By Feb 2025, 3, 197 patients were included (59. 8% UC, 40. 2% CD; median IQR age 45. 5 34. 5–59. 4 years and disease duration 4, 000 1, 999–7, 277 days), contributed 48, 732 observations, with per patient a mean of 3. 41 (SD 1. 10) time periods per year and 15. 2 in total. A total of 836 hospitalisations and 1, 182 ED visits occurred among 501 and 672 patients respectively. Higher odds of hospitalisation and ED visits were associated with EQ-5D pain/discomfort and limitations in usual activities, HBI and SCCAI total and general wellbeing scores, and SCCAI-reported blood in stool. Worse overall HRQoL was associated with increased ED use, while impaired self-care and overall health, higher HBI liquid stools and SCCAI bowel frequency were associated with hospitalisations (Table 1). Estimated annual costs for the full UK IBD population were £111, 234, 917 for hospitalisations and £13, 089, 422 for ED admissions (Table 2). Conclusion This large longitudinal patient-reported dataset allowed to identify key factors - including general wellbeing and pain/discomfort in addition to total scores - associated with hospital and ED use, highlighting their potential for targeted real-time risk stratification, and enabled estimation of related costs. Integrating remote monitoring into routine care may help enable proactive and cost-effective IBD management. References: (1) Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, et al. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res. 2019 Jul 30;17 (3): 365–74. (2) NHS 2022/23 National Cost Collection Data Publication. https: //www. england. nhs. uk/publication/2022-23-national-cost-collection-data-publication-2/. Accessed 17 Nov 2025. (3) Nartey Y, Ratna M, Card TR, et al. Incidence and prevalence of inflammatory bowel disease across the United Kingdom. University of Nottingham. 2021. https: //www. crohnsandcolitis. org. uk/media/pkamxda4/uonreport2021ᵢbdᵢncidandprev. pdf. Accessed 17 Nov 2025. Conflict of interest: Mrs. Fierens, Liselotte: No conflict of interest Clarke, Philip: No conflict of interest Dunbar, Grace: No conflict of interest Kormilitzin, Andrey: I hold research grants from: - the National Institute for Health and Care Research (UK) - GlaxoSmithKline - Pfizer - Alzheimer’s Research UK Matini, Lawrence: Speaker fees: AbbVie, Galapagos, Bristol Myers Squibb Punj Sharda, Anita: No conflict of interest Travis, Simon: Research Support: AbbVie, Celgene, Celsius, ECCO, Galapagos, GSK, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UKIERI, 35Bio, Vifor, and Norman Collisson Foundation Consulting Fees: Alimentiv Apexian Apollo Arcturis AstraZeneca BMS Clario Cosmo Dova Health Endpoint Health EQrX Equillium Ferring Galapagos Genentech/Roche Gilead GSK Janssen Iterative Health Lilly Mestag Microbiotica ONO Pfizer Phesi Protagonist Sanofi Satisfai Sensyne Health Spyre Takeda Teva Theravance Tr1X Bio Speaker fees: BMS, Ferring, GSK, Janssen, Lilly, Pfizer, Sun Pharma, Takeda. Share options: Dova Health Inc. Walsh, Alissa: Grant: Alfasigma, Helmsley Trust, Johnson & Johnson, Pfizer, Takeda Personal Fees: AbbVie, Alfasigma, Bristol Meyers Squibb, Dr Falk, Ferring, Johnson & Johnson, Lilly, Pfizer, Takeda, Tillotts Violato, Mara: No conflicts
Fierens et al. (Thu,) studied this question.